Stryker Corp. (SYK)

Stryker Corp (SYK) is facing a challenging environment in the medtech sector, characterized by weakness due to a post-Covid normalization and ongoing issues, including a cybersecurity attack that affected production. Despite these hurdles, experts largely recognize Stryker's strong market position, particularly in orthopedics, which continues to be a profitable segment for U.S. hospitals. The company has a robust relationship with medical professionals and is expected to grow its revenue at high single-digit rates. Analysts predict significant earnings growth, with a projected EPS of $15 by 2027, supported by an attractive valuation. As the population ages, the demand for artificial joints and robotic-assisted surgeries is expected to rise, positioning Stryker favorably in the long term.